These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 1576345)

  • 1. Immunopharmacokinetics of 111In-CYT-103 in ovarian cancer patients.
    Jusko WJ; Kung LP; Schmelter RF
    Targeted Diagn Ther; 1992; 6():177-90. PubMed ID: 1576345
    [No Abstract]   [Full Text] [Related]  

  • 2. 111In-CYT-103 immunoscintigraphy in ovarian cancer.
    Cannistra SA
    Gynecol Oncol; 1993 Nov; 51(2):292-4. PubMed ID: 8276314
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of 111In-CYT-103 on the surgical management of patients with ovarian cancer.
    Surwit EA
    Targeted Diagn Ther; 1992; 6():125-40. PubMed ID: 1576343
    [No Abstract]   [Full Text] [Related]  

  • 4. Multicenter clinical trial of 111In-CYT-103 in patients with ovarian cancer.
    Gallup DG
    Targeted Diagn Ther; 1992; 6():111-24. PubMed ID: 1576342
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical assessment of 111In-CYT-103 immunoscintigraphy in ovarian cancer.
    Surwit EA; Childers JM; Krag DN; Katterhagen JG; Gallion HH; Waggoner S; Mann WJ
    Gynecol Oncol; 1993 Mar; 48(3):285-92. PubMed ID: 8462896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncoscint for detection of disseminated colorectal and ovarian cancer.
    Med Lett Drugs Ther; 1993 Jun; 35(898):52-3. PubMed ID: 8497207
    [No Abstract]   [Full Text] [Related]  

  • 7. OncoScint image atlas.
    Maguire RT
    Targeted Diagn Ther; 1992; 6():141-75. PubMed ID: 1576344
    [No Abstract]   [Full Text] [Related]  

  • 8. Challenges in immunoscintigraphy of ovarian cancer.
    Kim EE; Kasi LP
    Gynecol Oncol; 1993 Mar; 48(3):283-4. PubMed ID: 8462895
    [No Abstract]   [Full Text] [Related]  

  • 9. A practical approach to planar and SPECT imaging of 111In-CYT-103.
    Collier BD; Trembath LA; Liu Y; Turoglu HT; Patel N; Thakur S
    Targeted Diagn Ther; 1992; 6():191-210. PubMed ID: 1576346
    [No Abstract]   [Full Text] [Related]  

  • 10. In-111 CYT-103 immunoscintigraphy of isolated splenic metastasis from ovarian carcinoma.
    Nguyen BD; Regan F
    Clin Nucl Med; 1997 Apr; 22(4):256-7. PubMed ID: 9099487
    [No Abstract]   [Full Text] [Related]  

  • 11. In-111 CYT-103 immunoscintigraphy in the imaging of ovarian carcinoma.
    Neal CE; Baker MR; Hilgers RD; Fanning J; Burke RC; Snodgrass J; Cull RD
    Clin Nucl Med; 1993 Jun; 18(6):472-6. PubMed ID: 8319398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results.
    Siegel BA; Dehdashti F; Mutch DG; Podoloff DA; Wendt R; Sutton GP; Burt RW; Ellis PR; Mathias CJ; Green MA; Gershenson DM
    J Nucl Med; 2003 May; 44(5):700-7. PubMed ID: 12732670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. False-positive imaging of In-111 labeled monoclonal antibody conjugate CYT-103 in a patient with metastatic colorectal carcinoma.
    Bhatia M; Baron PL; Alderman DF; Gordon L
    Clin Nucl Med; 1995 Nov; 20(11):979-80. PubMed ID: 8565379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation absorbed dose estimates for indium-111-labeled B72.3, an IgG antibody to ovarian and colorectal cancer: MIRD dose estimate report No. 18.
    Mardirossian G; Brill AB; Harwood SJ; Olsen J; Dwyer KA; Siegel JA
    J Nucl Med; 1998 Apr; 39(4):671-6. PubMed ID: 9544680
    [No Abstract]   [Full Text] [Related]  

  • 15. Indium-111 satumomab pendetide: the first FDA-approved monoclonal antibody for tumor imaging.
    Bohdiewicz PJ
    J Nucl Med Technol; 1998 Sep; 26(3):155-63; quiz 170-1. PubMed ID: 9755434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoscintigraphy of colorectal carcinoma utilizing 111In-labeled monoclonal antibody conjugate CYT-103.
    Neal CE; Swan TL; Baker MR; Ellis RL; Katterhagen JG
    Gastrointest Radiol; 1991; 16(3):251-5. PubMed ID: 1879645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian cancer: comparison of findings with perfluorocarbon-enhanced MR imaging, In-111-CYT-103 immunoscintigraphy, and CT.
    Low RN; Carter WD; Saleh F; Sigeti JS
    Radiology; 1995 May; 195(2):391-400. PubMed ID: 7724757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipomas as a potential cause for uptake of In-111 MAb72.3 (Oncoscint CR).
    Sakow NK; Japanwalla M; Tuckson WB; Shields RE
    Clin Nucl Med; 1996 Apr; 21(4):332-3. PubMed ID: 8925626
    [No Abstract]   [Full Text] [Related]  

  • 19. Multicenter clinical trials of monoclonal antibody B72.3-GYK-DTPA 111In (111In-CYT-103; OncoScint CR103) in patients with colorectal carcinoma.
    Abdel-Nabi HH; Doerr RJ
    Targeted Diagn Ther; 1992; 6():73-88. PubMed ID: 1576351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Site of mistletoe injection observed on In-111 OncoScint imaging.
    Choe W
    Clin Nucl Med; 1997 Feb; 22(2):127. PubMed ID: 9031776
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.